Feverfew for migraine prophylaxis: A systematic review

Journal of Dietary Supplements

Volumn 6, Issue 2, 2009, Pages 91-103

  Saranitzky, Elisa ^a,b   White, C Michael ^a,b   Baker, Erica L ^a,b   Baker, William L ^a,b   Coleman, Craig I ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Feverfew; Headache; Mi grane; Parthenolide; Tanacetum parthenium

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; PLANT EXTRACT;

ARTICLE; HUMAN; MIGRAINE; PHYTOTHERAPY; TANACETUM PARTHENIUM;

CYCLOOXYGENASE 2 INHIBITORS; HUMANS; MIGRAINE DISORDERS; PHYTOTHERAPY; PLANT EXTRACTS; TANACETUM PARTHENIUM;

TANACETUM PARTHENIUM;

EID: 67650666215     PISSN: 19390211     EISSN: None     Source Type: Journal    
DOI: 10.1080/19390210902861809     Document Type: Article

References (16)

1. Blau JN. Towards a definition of migraine headache. Lancet. 1984;1:444-445.
2. De Weerdt CJ, Bootsma HP, Hendriks H. Herbal medicines in migraine prevention: randomized, double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3:225-230.
3. 2-extract (MIG-99) in migraine prevention-a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia. 2005;25:1031-1041.
4. Heptinstall S, Awang DV, Dawson BA, Kindock D, Knight DW, May J. Parthenolide content and the bioactivity of feverfew (Tanacetum parthenium (L.) Schults-Bip.). Estimation of commercial and authenticated feverfew products. J Pharm Pharmacol. 1992;44(5):391-395.
5. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger, ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159:813-818.
6. Hwang D, Fischer NH, Jang BC, Tak H, Kim JK, Lee W. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun. 1996;226:810-818.
7. International Headache Society. The International Headache Classification. http://www.ihs-classification.org/en/ (accessed August 10,2007).
8. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
9. Johnson S. Feverfew: a traditional herbal remedy for migraine and arthritis. London: Sheldon Press, 1984.
10. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as a prophylactic treatment of migraine. BMJ. 1985;291:569-573.
11. Kuritzky A, Elhacham Y, Yerushalmi Z, Hering R. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology. 1994;44(Suppl. 2):A201.
12. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
13. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache. 2004;44:885-890.
14. Murphy J J, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled tiral of feverfew in migraine prevention. Lancet. 1988;2:189-192.
15. Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis-a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia. 2002;22:523-532.
16. White CM, Coleman CI. Drug induced cardiac diseases. In: T Dunsworth, M Richardson, J Cheng, et al. (Eds.), Pharmacotherapy self-assessment program, cardiology book 1 (6th ed.), pp. 39-56. Lenexa, KS: American College of Clinical Pharmacy, 2007.